what to do next for this man?

A colleague rang me this morning about a 65 year old man. background ischaemic cardiomyopathy -angio last week no targets for revascularisation suitable for a bivent ICD as EF 25% and has lbbb on ecg worsening heart failure - put on 3kg over past 24 hours on furosemide 80mg / 40 mg iv, spironolactone 25mg,  ramipril 2.5mg and bisoprolol 5mg BP 120 systolic, creatinine 110 , sodium now 122 (was normal 1 week ago)   what would you do next? sadian
Source: Doc2Doc BMJ Cardiology - Category: Cardiology Authors: Source Type: forums

Related Links:

Less is known about pregnancy in women with arrhythmogenic right ventricular cardiomyopathy (ARVC). From April 1995 to May 2018, 157 women with ARVC were retrospectively enrolled. Data on pregnancy and cardiac outcomes were analyzed. There were 224 pregnancies in 120 patients including 30 (13.4%) spontaneous and 2 (0.9%) medical abortions, 12 cardiac adverse events were recorded including new onset frequent premature ventricular contractions (PVC) in 3 (2.5%) patients, previous PVC numbers increased more than 100% in 5 (4.2%), syncope in 2 (1.7%), sustained ventricular tachycardia and heart failure required hospitalization...
Source: The American Journal of Cardiology - Category: Cardiology Authors: Source Type: research
Conclusion: Tafamidis is an effective and safe oral medication for the treatment of the cardiomyopathy of transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization. PMID: 31735059 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - Category: Drugs & Pharmacology Authors: Tags: Ann Pharmacother Source Type: research
ConclusionsLack of ALX/FPR2 induced obesity, reduced the lifespan, amplified leukocyte dysfunction, and facilitated profound inter-organ non-resolving inflammation. Our study shows the integrative and indispensable role of ALX/FPR2 in lipid metabolism, cardiac inflammation-resolution processes, obesogenic aging, and renal homeostasis.
Source: Molecular Metabolism - Category: Endocrinology Source Type: research
In this study, we investigated the role of miR-223-3p in experimental autoimmune myocarditis (EAM). We found that miR-223-3p expression was significantly lower in EAM mice than that in normal mice. miR-223-3p inhibited NLRP3 inflammasome expression, promoting the polarization of dendritic cells (DCs) towards a tolerogenic DC phenotype. miR-223-3p effectively induced regulatory T cell (Treg) generation by inhibiting the function of antigen-presenting DCs. Transfer of miR-223-3p-overexpressing DCs protected mice against the development of EAM. Our findings suggest that miR-223-3p is involved in the induction of the tolerogen...
Source: Molecular Immunology - Category: Allergy & Immunology Source Type: research
(University of Pennsylvania School of Medicine) Women who are diagnosed with peripartum cardiomyopathy (PPCM) during late pregnancy or within a month following delivery are more likely to experience restored cardiac function and improved outcomes compared to those who are diagnosed later in the postpartum period, according to a new study. The findings underscore the need for increased awareness and monitoring of heart failure symptoms, particularly among black women, who, on average, are diagnosed significantly later than white patients, researchers found.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
ConclusionsOPTM of SERCA2 correlate with myocardial fibrosis in NICM. In younger patients, OPTM of SERCA2 correlate with elevated BNP and increased composite MACE.
Source: IJC Heart and Vasculature - Category: Cardiology Source Type: research
Condition:   Heart Failure Intervention:   Other: Kansas City Cardiomyopathy Questionnaire-12 Sponsor:   Stanford University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Heart Failure Intervention:   Other: Kansas City Cardiomyopathy Questionnaire-12 Sponsor:   Stanford University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Heart Failure Intervention:   Other: Kansas City Cardiomyopathy Questionnaire-12 Sponsor:   Stanford University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Heart Failure Intervention:   Other: Kansas City Cardiomyopathy Questionnaire-12 Sponsor:   Stanford University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Bisoprolol | Cardiology | Cardiomyopathy | Furosemide | Heart | Heart Failure | Spironolactone